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PXPEDITED REVIEW
he Unrestricted Use of Paclitaxel-
ersus Sirolimus-Eluting Stents for
oronary Artery Disease in an Unselected Population
ne-Year Results of the Taxus-Stent Evaluated At
otterdam Cardiology Hospital (T-SEARCH) Registry
ndrew T. L. Ong, MBBS, FRACP, Patrick W. Serruys, MD, PHD, FACC, Jiro Aoki, MD,
ngela Hoye, MBCHB, MRCP, Carlos A. G. van Mieghem, MD, Gaston A. Rodriguez-Granillo, MD,
arco Valgimigli, MD, Karel Sonnenschein, Evelyn Regar, MD, PHD, Martin van der Ent, MD, PHD,
eter P. T. de Jaegere, MD, PHD, Eugene P. McFadden, MBCHB, MD, FRCPI, FACC,
eorgios Sianos, MD, PHD, Willem J. van der Giessen, MD, PHD, Pim J. de Feyter, MD, PHD, FACC,
on T. van Domburg, PHD
otterdam, the Netherlands
OBJECTIVES We investigated the efficacy of paclitaxel-eluting stents (PES) compared to sirolimus-eluting
stents (SES) when used without restriction in unselected patients.
BACKGROUND Both SES and PES have been separately shown to be efficacious when compared to bare
stents. In unselected patients, no direct comparison between the two devices has been
performed.
METHODS Paclitaxel-eluting stents have been used as the stent of choice for all percutaneous coronary
interventions in the prospective Taxus-Stent Evaluated At Rotterdam Cardiology Hospital
(T-SEARCH) registry. A total of 576 consecutive patients with de novo coronary artery
disease exclusively treated with PES were compared with 508 patients treated with SES from
the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH)
registry.
RESULTS The PES patients were more frequently male, more frequently treated for acute myocardial
infarction, had longer total stent lengths, and more frequently received glycoprotein IIb/IIIa
inhibitors. At one year, the raw cumulative incidence of major adverse cardiac events was
13.9% in the PES group and 10.5% in the SES group (unadjusted hazard ratio [HR] 1.33,
95% confidence interval [CI] 0.95 to 1.88, p  0.1). Correction for differences in the two
groups resulted in an adjusted HR of 1.16 (95% CI 0.81 to 1.64, p  0.4, using significant
univariate variables) and an adjusted HR of 1.20 (95% CI 0.85 to 1.70, p  0.3, using
independent predictors). The one-year cumulative incidence of clinically driven target vessel
revascularization was 5.4% versus 3.7%, respectively (HR 1.38, 95% CI 0.79 to 2.43, p 0.3).
CONCLUSIONS The universal use of PES in an unrestricted setting is safe and is associated with a similar
adjusted outcome compared to SES. The inferior trend in crude outcome seen in PES was
due to its higher-risk population. A larger, randomized study enrolling an unselected
population may assist in determining the relative superiority of either device. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.008Cardiol 2005;45:1135–41) © 2005 by the American College of Cardiology Foundation
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(irolimus-eluting stents (SES, Cypher, Cordis, Johnson
nd Johnson, Miami Lakes, Florida) (1) and paclitaxel-
luting stents (PES, TAXUS, Boston Scientific Corp.,
atick, Massachusetts) (2) have both been independently
hown to reduce the need for repeat intervention when
ompared to bare-metal stents (BMS) in separate random-
zed clinical trials. The Food and Drug Administration
pprovals for these devices were granted in 2003 and 2004,
espectively, and it is estimated that drug-eluting stents
From the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
tudy supported by the Erasmus Medical Center, Rotterdam, and by unrestricted
nstitutional grants from Boston Scientific Corporation and Cordis, Johnson &
ohnson company.(
Manuscript received November 26, 2004; revised manuscript received January 10,
005, accepted January 18, 2005.DES) currently comprise 70% of the stent market in the
.S. The randomized controlled trials on which approval
as granted enrolled highly selected patients with single
esions that could be covered with one DES and were
ompared against BMS which is not representative of daily
linical practice.
Our group has previously published the results of the
apamycin-Eluting Stent Evaluated At Rotterdam Cardi-
logy Hospital (RESEARCH) registry, which demon-
trated that routine implantation of SES resulted in a
eduction in major adverse cardiac events (MACE), princi-
ally driven by a reduction in target vessel revascularization
TVR) when compared with a historical BMS control group
3). The PES were commercialized subsequent to SES, based
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Paclitaxel- Versus Sirolimus-Eluting Stents April 5, 2005:1135–41n the results of randomized controlled trials (4,5). The
eneficial effect of PES in patients treated in daily practice
emains to be defined. The aim of this study was to report the
ne-year outcomes of unrestricted/universal use of PES in
atients with de novo coronary artery lesions and to compare
ts efficacy against our historical SES cohort (3).
ETHODS
tudy design and patient population. The Taxus-Stent
valuated At Rotterdam Cardiology Hospital (T-SEARCH)
egistry is a prospective single-center registry with the main
urpose of evaluating the safety and efficacy of PES implan-
ation for consecutive unselected patients treated in daily
ractice. Its conceptual design and methodology are similar to
hat of the RESEARCH registry (6) and follows the dynamic
egistry design described by Rothman and Greenland (7).
Since February 16, 2003, when PES was granted Con-
ormité Européenne approval, it replaced SES as the default
tent for every percutaneous coronary intervention. Up until
eptember 30, 2003, a total of 576 patients with de novo
esions were treated exclusively with PES and are included
n the present report (PES group). This comprised 83.7% of
ll patients with de novo disease who received coronary
tents. In this period, only 12 patients received BMS
xclusively (11 were due to requirement for stents 3.5mm,
patient had elevated liver enzymes that precluded long-
erm clopidogrel therapy). Patients treated with PES and
MS in the same procedure (20 patients), those treated
ith PES and SES (20 patients), those treated with SES
nly (15 patients), and patients enrolled in other drug-
luting trials (44 patients) were not included in the present
eport. The PES are available in diameters of 2.25 mm, 2.5
m, 3.0 mm, and 3.5 mm and in lengths of 8 to 32 mm in
-mm increments for each available diameter.
This PES group was compared with a control group that
omprised the active arm of the RESEARCH registry, that
s the 508 patients with de novo disease treated solely with
Abbreviations and Acronyms
BMS  bare-metal stent
CI  confidence interval
CK-MB  creatine kinase-MB
DES  drug-eluting stent
HR  hazard ratio
MACE  major adverse cardiac event
MI  myocardial infarction
PES  paclitaxel-eluting stent
RESEARCH  Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital
SES  sirolimus-eluting stent
TIMI  Thrombolysis In Myocardial Infarction
T-SEARCH  Taxus-Stent Evaluated At Rotterdam
Cardiology Hospital
TVR  target vessel revascularizationES (SES group). Thus, the report consists of 1,084 hatients treated with DES, differentiated by the type of drug
oating on the stent, either sirolimus or paclitaxel.
rocedures and postintervention medications. Interven-
ions were performed according to current standard proce-
ures, with the final interventional strategy (including direct
tenting, postdilation, periprocedural glycoprotein IIb/IIIa
nhibitor, and use of intravascular ultrasound) left entirely
p to the operator’s discretion (6). Angiographic success was
efined as residual stenosis 30% by visual analysis in the
resence of Thrombolysis In Myocardial Infarction (TIMI)
ow grade 3. Patients were advised to maintain lifelong
spirin (at least 80 mg/day) and were pretreated with 300
g clopidogrel. Postprocedural clopidogrel treatment dif-
ered between the two groups. Patients treated with PES
ere prescribed at least six months of clopidogrel (75
g/day), based on existing data from randomized, con-
rolled trials (5). For patients treated with SES, clopidogrel
as prescribed for at least three months, unless one of the
ollowing was present (in which case clopidogrel was main-
ained for at least six months): multiple SES implantation
3 stents), total stent length 36 mm, chronic total
cclusion, and bifurcations.
nd point definitions and clinical follow-up. The pri-
ary outcome was the occurrence of MACE, defined as a
omposite of: 1) all cause death, 2) nonfatal myocardial
nfarction (MI), or 3) TVR. Myocardial infarction was
iagnosed by a rise in the creatine kinase-MB fraction
CK-MB) of more than three times the upper limit of
ormal according to American Heart Association/American
ollege of Cardiology guidelines (8). In patients who
nderwent coronary artery bypass surgery during the
ollow-up period, a periprocedural MI was diagnosed by a
ise in the CK-MB level of five times the upper limit of
ormal (9). For patients who presented with an acute MI, a
iagnosis of re-MI in the acute phase required a fall and rise
f CK-MB of 50% above the previous level (10). Target
esion revascularization was defined as a repeat intervention
surgical or percutaneous) to treat a luminal stenosis within
he stent or in the 5-mm distal or proximal segments
djacent to the stent. Target vessel revascularization was
efined as a re-intervention driven by any lesion located in
he same epicardial vessel. Thrombotic stent occlusion was
efined as angiographically documented complete occlusion
TIMI flow grade 0 or 1) or flow-limiting thrombus (TIMI
ow grade 1 or 2) in a previously successfully treated artery.
committee of three cardiologists (A.O., J.A., and E.M.F.)
eviewed all MACE.
All patients underwent clinical follow-up. Information
bout the in-hospital outcomes was obtained from our
nstitutional electronic clinical database and by review of
he hospital records for those discharged to referring hos-
itals (patients were referred from a total of 14 local
ospitals). Postdischarge survival status was obtained from
he Municipal Civil Registries at 1, 6, and 12 months. All
epeat interventions (surgical and percutaneous) and re-
ospitalizations were prospectively collected during the
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April 5, 2005:1135–41 Paclitaxel- Versus Sirolimus-Eluting Stentsollow-up. Questionnaires regarding adverse events, anginal
tatus, and medication use were sent to all living patients at
and 12 months. Referring physicians and institutions were
ontacted for additional information if required.
In both groups, follow-up coronary angiography was
linically driven by symptoms or signs suggestive of myo-
ardial ischemia or mandated by the operator at the end of
he index procedure predominantly for complex procedures.
n the PES group, three specific subgroups were restudied:
eft main stem stenting, crush-bifurcation procedures, and
atients who were concomitantly in a vulnerable plaque
tudy involving non-treated vessels (in total, 27% [n  154]
f PES patients underwent re-study during follow-up,
ncluding 14% [n  81] that were clinically driven). In the
ES group, the following “complex patient” subgroups were
e-studied: bifurcation lesions, left main stem stenting,
hronic total occlusions, very small vessels, long stent length
36 mm), and acute MI (in total, 40% [n  204] of SES
atients were re-studied, including 8% [n  40] that were
linically driven). Because of the well-known effect of
ngiographic re-evaluation in increasing the incidence of
epeat revascularization (11), all re-interventions were ret-
ospectively adjudicated and classified as either clinically
riven or non-clinically driven. Clinically driven repeat
evascularization was defined as any intervention motivated
y a significant luminal stenosis (50% diameter stenosis)
n the presence of anginal symptoms and/or proven myo-
ardial ischemia in the target vessel territory by noninvasive
esting.
tatistical analysis. Continuous variables are presented as
ean  standard deviation, and were compared using the
tudent unpaired t test. Categorical variables are presented
s counts and percentages and compared by means of the
isher exact test. All statistical tests were two-tailed. Pa-
ients lost to follow-up were considered at risk until the date
f last contact, at which point they were censored. The
umulative incidence of adverse events was estimated ac-
ording to the Kaplan-Meier method, and Cox proportional
azards models were used to assess differences between the
wo strategies. Separate Cox regression analyses were per-
ormed to identify independent predictors of adverse events,
sing clinical, angiographic, and procedural variables con-
ained in Tables 1 and 2. The Cox proportional hazards
egression models were used to control for differences
etween groups, and the final results are presented as
djusted hazard ratios (HRs).
ESULTS
aseline and procedural characteristics. The PES pa-
ients were more often male, had more MI as their present-
ng symptom, more cardiogenic shock, more complex le-
ions treated, longer total stent lengths, and more frequently
eceived glycoprotein IIb/IIIa inhibitors (Tables 1 and 2).
ewer PES patients had a history of previous bypass
urgery, and fewer segments per patient were stented, ulthough the number of vessels treated per patient was
dentical. Other baseline and procedural characteristics were
imilar.
linical outcome. FIRST 30 DAYS. No significant differ-
nces were noted between groups with respect to the
ncidences of death, death or MI, TVR, or MACE in the
rst month (Table 3). Mortality in the first 30 days was
.1% in the PES group and 1.6% in the SES group (p 
.7). In both groups, most deaths occurred in patients with
ardiogenic shock. Angiographically proven stent thrombo-
is occurred in six patients in the PES group, four of whom
ere treated for AMI, the other two presented with
nstable angina. Two patients with AMI also underwent
ifurcation stenting, as did one with unstable angina. In
otal, three patients with bifurcation stenting experienced
tent thrombosis. In the SES group, two patients were
iagnosed with stent thrombosis. One patient died as a
esult of stent thrombosis in the PES group.
NE YEAR. The MACE components are presented in Fig-
res 1 and 2. At one year, 5.3% of patients in the PES group
nd 3.4% in the SES group had died (HR 1.69, 95%
onfidence interval [CI] 0.93 to 3.00, p  0.08). In total,
.8% of patients in the PES group versus 7.0% in the SES
roup had either died or suffered a nonfatal re-MI (HR
.28, 95% CI 0.84 to 1.95, p 0.3). The incidence of TVR
as similar in the SES and PES groups: 7.3% versus 5.1%
HR 1.31, 95% CI 0.81 to 2.13, p  0.3). Clinically driven
VR was reduced by a similar magnitude in both groups,
pecifically 3.7% versus 5.4%, respectively (HR 1.38, 95%
I 0.79 to 2.43, p  0.3). Post-hoc analysis of clinically
riven TVR demonstrates that confidence limits crossed
able 1. Baseline Characteristics
SES Group
(n  508)
PES Group
(n  576) p Value
ale, % 68 74 0.04
ge, yrs  SD 61  11 62  11 0.4
iabetes, % 18 18 0.8
on–insulin-dependent, % 12 13 0.5
nsulin-dependent, % 6 5 0.7
ypertension, % 41 42 0.9
ypercholesterolemia, % 56 62 0.03
urrent smoking, % 31 29 0.6
revious myocardial
infarction, %
30 35 0.13
revious angioplasty, % 19 18 0.8
revious coronary bypass
surgery, %
9 6 0.05
ingle-vessel disease, % 46 44 0.5
ultivessel disease, % 54 56 0.5
linical presentation  0.001
Stable angina, % 45 45
Unstable angina, % 37 27
Acute myocardial
infarction, %
18 28
Cardiogenic shock, %* 10 13
Relative to patients with acute myocardial infarction.
PES  paclitaxel-eluting stent; SES  sirolimus-eluting stent.nity, with point estimates close to unity in the subgroups
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Paclitaxel- Versus Sirolimus-Eluting Stents April 5, 2005:1135–41nalyzed (Fig. 3). Regarding the primary end point of
ACE (the composite of death, MI, or TVR), Kaplan-
eier estimates were 13.9% in the PES group versus 10.5%
n the SES group (unadjusted HR 1.33, 95% CI 0.95 to
.88, p  0.10).
There were two cases of late (6 months to 1 year) stent
hrombosis documented angiographically in the PES group.
n one, it occurred eight months after the index procedure
hile the patient was on antiplatelet monotherapy with
spirin. The second occurred 11 months after the index
rocedure after the patient had temporarily suspended
ntiplatelet therapy (aspirin) for noncardiac surgery.
redictors of adverse events. To assess the independent
redictors of MACE at one year, two separate multivariate
nalyses were performed. First, a model was built using all
aseline and procedural characteristics shown in Tables 1
nd 2. Forward stepwise regression was performed with
ntry and stay criteria of 0.05 and 0.10, respectively. The
Table 2. Procedural Characteristics
Treated vessel
Left anterior descending, %
Left circumflex, %
Right coronary artery, %
Left main coronary, %
Bypass graft, %
Lesion type*
Type A or B1, %
Type B2 or C, %
Multivessel treatment, %
Glycoprotein IIb/IIIa inhibitor, %
Clopidogrel prescription, months  SD
Bifurcation stenting, %
No. of stented segments  SD
No. of stented vessels  SD
No. of implanted stents  SD
Total stented length per patient, mm  SD
Nominal stent diameter 2.5 mm, %
Total stent length 33 mm, %
Angiographic success of all lesions, %
*Percentage of patients with at least 1 lesion type within the
Abbreviations as in Table 1.
able 3. Major Adverse Cardiac Events in the First Month
ollowing Stent Implantation
0 to 1 Month
SES Group
(n  508)
PES Group
(n  576) p Value*
eath, n (%) 8 (1.6) 12 (2.1) 0.7
onfatal myocardial
infarction, n (%)
12 (2.4) 17 (3.0) 0.6
arget lesion revascularization,
n (%)
6 (1.2) 7 (1.2) 1.0
arget vessel revascularization,
n (%)†
6 (1.2) 13 (2.3) 0.2
ny event, n (%) 23 (4.5) 34 (5.9) 0.3
tent thrombosis, n (%)‡ 2 (0.4) 6 (1.0) 0.3
By Fisher exact test. †Includes target lesion revascularization. ‡Angiographicallyc
ocumented stent thrombosis requiring repeat intervention.
Abbreviations as in Table 1.ollowing variables were significant: cardiogenic shock, fe-
ale gender, multivessel disease, diabetes mellitus, left main
tenting, bifurcation stenting, and lesion type B2/C (Table
). A second model built using the same variables with the
nd point of TVR at one year revealed bifurcation stenting
as the only significant independent predictor of TVR.
djustment for differences between groups. The Cox
egression models were used to adjust the two groups by
orrecting for multiple potential confounders in the baseline
nd procedural characteristics. First, a model was built
orcing stent type and all independent predictors from Table
(see Table 5). All previously significant variables remained
ignificant except for lesion type B2/C. The adjusted HR
or use of PES became even less significant, decreasing from
.33 (95% CI 0.95 to 1.88, p  0.10) to 1.20 (95% CI 0.85
o 1.70, p  0.3), after controlling for the increased
omplexity in the PES group.
A second model was then built forcing stent type and
ignificant univariate variables (independent predictors plus
otal stent length and number of stents), and the adjusted
utcome of MACE at one year was similar between SES
nd PES (adjusted HR 1.16, 95% CI 0.81 to 1.64, p 0.4).
Finally, stent type was also not a significant predictor of
VR when adjusted for bifurcation stenting (adjusted HR
.33, 95% CI 0.82 to 2.15, p  0.25).
ISCUSSION
he major finding of this report is that the unrestricted use
f PES in de novo lesions is associated with a nonsignificant
ifference in outcome compared to SES, both unadjusted
nd when controlled for significant baseline and procedural
S Group
 508)
PES Group
(n  576) p Value
59 55 0.3
32 33 0.6
39 38 0.9
3 4 0.3
3 3 1.0
47 32  0.001
76 87  0.001
32 29 0.3
19 28 0.002
.0  2.0 6  0  0.05
16 16 0.9
.0  1.0 1.7  0.9  0.001
.3  0.6 1.3  0.6 0.8
.1  1.4 2.2  1.5 0.09
.7  23.7 42.9  31.2 0.02
36 35 0.7
45 48 0.5
97 97 0.9
ory.SE
(n
4
2
1
2
38haracteristics. The trend toward an inferior crude outcome
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April 5, 2005:1135–41 Paclitaxel- Versus Sirolimus-Eluting Stentsith PES was due to the more complex characteristics of the
roup.
The two sequential registries were separated by a four-
onth interval. Several differences in baseline characteristics
ere noted. More MIs including patients in cardiogenic
hock were treated in the T-SEARCH registry because of
he implementation of a local pre-hospital protocol that
riaged more patients to primary percutaneous coronary
ntervention. More complex lesions were treated in the
-SEARCH registry, with a shift from type A/B1 to B2/C
esions, with more stents being implanted in the T-SEARCH
egistry. This in part reflects the increased complexity of cases
eing performed with time and as operators and referring
hysicians becoming more aware and familiar with DES.
The primary end point of this trial was overall MACE,
nd the results for this comparison are presented both unad-
igure 1. Unadjusted Kaplan-Meier event curves at one year. (A) Cumul
umulative risk of death, myocardial infarction, or target vessel revascu
irolimus-eluting stent.usted and following adjustment for significant predictive mariables (Table 5). With the commercialization of PES, our
nstitution switched completely from SES to PES, precluding
andomization. Therefore, it was intuitive to present the data
s such and imperative to statistically correct by using signifi-
ant predictive variables to account for the increased complex-
ty seen in the PES group. To preserve the prospective,
onsecutive, and unselected nature of both registries, and the
equirement to control for multiple significant variables, the
ox regression model was used. Our results demonstrate that,
ollowing adjustment, the HR was closer to unity compared to
he crude result, further confirming the increased complexity in
he PES group.
The multivariate analysis (Table 4) for independent
redictors of MACE is unique as it is an analysis of 1,084
ES patients treated in an unrestricted setting. In a total
ohort of DES patients, cardiogenic shock, female gender,
risk of death. (B) Cumulative risk of death or myocardial infarction. (C)
ion. CI  confidence interval; PES  paclitaxel-eluting stent; SES ative
larizatultivessel disease, diabetes mellitus, left main stenting,
b
s
p
m
f
d
d
w
u
c
c
t
(
i
o
r
s
b
1
T
S
R
t
s
B
w
d
o
s
T
s
t
t
t
t
r
F
v
F
b
T
E
M
T
*
l
1140 Ong et al. JACC Vol. 45, No. 7, 2005
Paclitaxel- Versus Sirolimus-Eluting Stents April 5, 2005:1135–41ifurcation stenting, and treatment of a complex lesion
ignificantly predicted an adverse outcome. From this list,
atients who possess these characteristics should undergo
ore regular clinical surveillance.
The major advantage of DES has been to reduce the need
or repeat revascularization (1–3). In our study, the inci-
ence TVR at one year with PES was not significantly
ifferent from the results obtained with SES. Furthermore,
hen the adjusted end point of clinically driven TVR was
sed (Fig. 2), similar outcomes were reproduced, thus
onfirming that both drug-eluting systems serve to reduce
linical restenosis in an unselected population.
A nonsignificantly higher incidence of angiographic stent
hrombosis in the first 30 days was noted in the PES cohort
1.0% in SES vs. 0.4% in PES, p  0.3). However, it is
mportant to emphasize that, owing to the infrequent
ccurrence of this event, large numbers of patients are
equired to assess this complication properly. We have
igure 2. Unadjusted one-year cumulative risk of clinically driven target
essel revascularization. Abbreviations as in Figure 1.igure 3. Hazard ratios (HR) of stent type at one-year follow-up for clinically d
aseline and procedural characteristics. MI  myocardial infarction; other abbrhown that in a larger population, the incidence rates in
oth DES were in the same range: 1.0% (95% CI 0.6% to
.9%) in PES and 1.0% (95% CI 0.5% to 1.8%) in SES (12).
At the time the T-SEARCH registry was conducted,
AXUS II (5) and the Randomized Comparison of a
irolimus-Eluting Stent with a Standard Stent for Coronary
evascularization (RAVEL) (13) were the two published
rials available with one-year MACE results from the eluting
tent arms of 10.9% (slow-release arm) and 5.8%, respectively.
ased on those results, the group sample sizes of our study
ould have been adequately powered to show a difference.
Subsequent to that, the results of larger trials of both
evices—TAXUS IV and Sirolimus-Eluting Stent in Cor-
nary Lesions (SIRIUS)—were published and demon-
trated a smaller difference (8.4% vs. 7.1%, respectively).
he population of this registry is an all-inclusive unre-
tricted one, a sample that is representative of the popula-
ion seen in a tertiary catheterization laboratory. Therefore,
his population is directly comparable to daily practice and
he results do not require extrapolation as for randomized
rials. The results of this registry complement published
andomized trials.
able 4. Multivariate Predictors of Major Adverse Cardiac
vents at One Year (Cox Proportional Hazards Model)
HR 95% CI p Value
ajor adverse cardiac events*
Cardiogenic shock (stable angina
as reference variable)
4.54 2.44–8.48  0.001
Female gender 1.72 1.22–2.43 0.002
Multivessel disease 1.74 1.19–2.55 0.005
Diabetes mellitus 1.65 1.12–2.42 0.01
Left main stenting 1.96 1.10–3.48 0.02
Bifurcation stenting 1.59 1.06–2.38 0.03
Lesion type B2 or C 1.85 1.01–3.40 0.047
arget vessel revascularization
Bifurcation stenting 2.77 1.68–4.57  0.001
Major adverse cardiac events: death, myocardial infarction, or target vessel revascu-
arization.
CI  confidence interval; HR  hazard ratio.riven target vessel revascularization in subgroups of patients according to
eviations as in Figure 1.
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April 5, 2005:1135–41 Paclitaxel- Versus Sirolimus-Eluting StentsONCLUSIONS
he universal use of PES in an unrestricted setting is safe,
nd associated with a non-significant adjusted difference in
utcome at one year compared to SES, with a trend toward
orse outcomes in the PES cohort, in part owing to its
igher-risk profile. Both DES reduce the need for repeat
ntervention in the real world setting of complex patient and
rocedural characteristics.
eprint requests and correspondence: Prof. Patrick W. Serruys,
horaxcenter, Bd-406, Dr. Molewaterplein 40, 3015-GD Rotter-
am, the Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
EFERENCES
1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus
standard stents in patients with stenosis in a native coronary artery.
N Engl J Med 2003;349:1315–23.
2. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-
eluting stent in patients with coronary artery disease. N Engl J Med
able 5. Hazard Ratios by Stent Type of Major Adverse
ardiac Events After Adjustment*
HR 95% CI p Value
ACE†
Unadjusted 1.33 0.95–1.88 0.10
Adjusted for significant predictors
of MACE
1.20 0.85–1.70 0.3
Adjusted for significant univariate
variables‡
1.16 0.81–1.64 0.4
VR
Unadjusted 1.31 0.81–2.13 0.26
Adjusted for significant predictors
of TVR
1.33 0.82–2.15 0.25
Stent type coded as: 0  sirolimus-eluting stent, 1  paclitaxel eluting stent. †Major
dverse cardiac events: death, myocardial infarction, or target vessel revascularization
TVR). ‡Significant univariate variables for major adverse cardiac event (MACE)
ere the significant predictors plus total stent length and number of stents implanted.
Abbreviations as in Table 4.2004;350:221–31.3. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted
utilization of sirolimus-eluting stents compared with conventional bare
stent implantation in the “real world”: the Rapamycin-Eluting Stent
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.
Circulation 2004;109:190–5.
4. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and
twelve-month results from a randomized, double-blind trial on a
slow-release paclitaxel-eluting stent for de novo coronary lesions.
Circulation 2003;107:38–42.
5. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to
assess the effectiveness of slow- and moderate-release polymer-based
paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;
108:788–94.
6. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after
sirolimus-eluting stent implantation in patients with acute coronary
syndromes: insights from the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll
Cardiol 2003;41:2093–9.
7. Rothman KJ, Greenland S. Cohort studies. In: Rothman KJ, Green-
land S, editors. Modern Epidemiology. 2nd edition. Philadelphia, PA:
Lippincott Williams & Wilkins Publishers, 1998:79–80.
8. Smith SC, Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines of
percutaneous coronary interventions (revision of the 1993 PTCA
guidelines). A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
(Committee to Revise the 1993 Guidelines for Percutaneous Trans-
luminal Coronary Angioplasty). J Am Coll Cardiol 2001;37:2239i–
lxvi.
9. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery
bypass surgery and stenting for the treatment of multivessel disease.
N Engl J Med 2001;344:1117–24.
0. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty
with stenting, with or without abciximab, in acute myocardial infarc-
tion. N Engl J Med 2002;346:957–66.
1. Ruygrok PN, Melkert R, Morel MA, et al. Does angiography six
months after coronary intervention influence management and out-
come? Benestent II Investigators. J Am Coll Cardiol 1999;34:1507–
11.
2. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month
clinical outcome of thrombotic stent occlusion following bare metal,
sirolimus or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:
944–50.
3. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison
of a sirolimus-eluting stent with a standard stent for coronary revas-
cularization. N Engl J Med 2002;346:1773–80.
